Peer-reviewed study reports a 78% reduction in hospital-wide CLABSI rates from 2023 to 2024 MISSISSAUGA, Ontario / Sep 16, 2025 / Business Wire / Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, today announced the publication of results from a peer-reviewed clinical study investigating the use of Covalon’s VALGuard® Vascular Access Line Guard in the... Read More